Abstract
Chronic itch is a troublesome condition and often difficult to cure. Emerging evidence suggests that the periaqueductal gray (PAG)-rostral ventromedial medulla (RVM) pathway may play an important role in the regulation of itch, but the cellular organization and molecular mechanisms remain incompletely understood. Here, we report that a group of RVM neurons distinctively express the G-protein-coupled estrogen receptor (GPER), which mediates descending inhibition of itch. We found that GPER+ neurons in the RVM were activated in chronic itch conditions in rats and mice. Selective ablation or chemogenetic suppression of RVM GPER+ neurons resulted in mechanical alloknesis and increased scratching in response to pruritogens, whereas chemogenetic activation of GPER+ neurons abrogated itch responses, indicating that GPER+ neurons are antipruritic. Moreover, GPER-deficient mice and rats of either sex exhibited hypersensitivity to mechanical and chemical itch, a phenotype reversible by the µ type opioid receptor (MOR) antagonism. Additionally, significant MOR phosphorylation in the RVM was detected in chronic itch models in wild-type but not in GPER−/− rats. Therefore, GPER not only identifies a population of medullary antipruritic neurons but may also determine the descending antipruritic tone through regulating µ opioid signaling.
SIGNIFICANCE STATEMENT Therapeutic options for itch are limited because of an as yet incomplete understanding of the mechanisms of itch processing. Our data have provided novel insights into the cellular organization and molecular mechanisms of descending regulation of itch in normal and pathologic conditions. GPER+ neurons (largely GABAergic) in the RVM are antipruritic neurons under tonic opioidergic inhibition, activation of GPER promotes phosphorylation of MOR and disinhibition of the antipruritic GPER+ neurons from inhibitory opioidergic inputs, and failure to mobilize GPER+ neurons may result in the exacerbation of itch. Our data also illuminate on some of the outstanding questions in the field, such as the mechanisms underlying sex bias in itch, pain, and opioid analgesia and the paradoxical effects of morphine on pain and itch.
Introduction
The periaqueductal gray (PAG)-rostral ventromedial medulla (RVM) system plays a well-established role in the descending modulation of pain transmission in the spinal cord (Denk et al., 2014; Kim et al., 2018; Liu et al., 2018; Chen and Heinricher, 2019). RVM, consisting of the midline nucleus raphe magnus and the adjacent reticular structures, receives extensive projections from PAG and in turn exerts bidirectional (inhibition or facilitation) influences on spinal cord pain transmission. These effects have been attributed to the activity of electrophysiologically identified ON and OFF neurons, which are presumed to mediate facilitation and inhibition of pain, respectively (Fields et al., 1983; 1991; Mason et al., 1992). In addition, the PAG-RVM system may also be crucial for itch regulation. Activation of Tac1+ neurons in ventrolateral PAG was found to induce spontaneous scratching in mice. Notably, this effect was relayed by RVM neurons, the identity of which remains to be determined (Gao et al., 2019).
Serotonergic neurons constitute approximately one-fourth of the total neuronal population in RVM (Gu and Wessendorf, 2007). Accumulating evidence indicates that RVM serotonergic neurons may play a role in facilitating itch. Accordingly, mice lacking 5-HT neurons in the RVM showed attenuated pruritic behavior evoked by compound 48/80 (Liu et al., 2014). Pharmacological ablation of bulbospinal serotonergic (5-HT) fibers also significantly reduced the number of scratching elicited by chloroquine (CQ). Furthermore, the bulbospinal serotonergic fibers facilitate itch by augmenting gastrin-releasing peptide (GRP)–gastrin-releasing peptide receptor (GRPR) signaling via the 5-HT1A receptor (Zhao et al., 2014). Until recently, however, little is known about the role of the nonserotonergic neurons in the RVM in itch regulation. Electrophysiologically identified ON and OFF neurons, largely nonserotonergic neurons (Potrebic et al., 1994; Mason, 1997), exhibit opposing activity in response to intradermally applied pruritogens (Follansbee et al., 2018), suggesting that they may play differential roles in regulation of itch in addition to regulation of pain. It is possible that in addition to the itch-facilitating serotonergic neurons there may be a different population of antipruritus neurons in the RVM. Identification of this new population of antipruritus neurons in the RVM will be a major step forward in understanding the mechanisms of itch.
Opioid signaling is predominant within the PAG-RVM system. Indeed, the PAG-RVM is enriched with the µ type opioid receptor (MOR), the activation of which results in powerful analgesia (Meng et al., 1998; Eippert et al., 2009; Harasawa et al., 2016). However, itch is one of the most common side effects of µ opioids. The mechanisms underlying the differential effects of MOR activation on pain and itch remain to be determined. Nevertheless, there has been indirect evidence suggesting that MOR located at supraspinal structures such as the RVM may mediate opioid-induced itch both in rodents and in primates (Ko et al., 2004; Moser and Giesler, 2014; Ding et al., 2015).
Previous reports indicate that the PAG-RVM system is sexually dimorphic, and morphine preferentially activates the PAG-RVM pathway in rats (Loyd and Murphy, 2006; Loyd et al., 2007). This raises the possibility that estrogen might inhibit opioid signaling in the PAG-RVM system, thereby contributing to the well-documented gender differences in pain, itch, and opioid analgesia (Green et al., 2006; Sanoja and Cervero, 2010; Mogil, 2012; Stumpf et al., 2013; Verzillo et al., 2014; Abraham et al., 2018). This possibility is quite likely because 17β-estradiol (E2) may rapidly uncouple MOR from activating the G-protein-regulated inwardly rectifying potassium channel (GIRK; Lagrange et al., 1997) and that µ opioid analgesia is primarily mediated through activation of GIRK (Blanchet and Lüscher, 2002). E2 acts by activating nuclear receptors Erα (Erβ) or the G-protein-coupled estrogen receptor (GPER). We have recently demonstrated that in human neuroblastoma SH-SY5Ycells, activation of GPER promotes MOR phosphorylation in a calcium-PKC-dependent manner (Ding et al., 2019). Furthermore, in pilot experiments we found that the RVM is enriched with GPER and MOR. These data have led us to postulate that GPER-mediated inhibition of MOR signaling may play certain roles in descending control of itch, which has been tested in this investigation.
Materials and Methods
Animals
Gper-Cre mice (female, 10 weeks old), GPER−/− mice (male and female, 8–10 weeks old), GPER−/− rats (male and female, 10–12 weeks old), and age and gender-matched WT controls were used for experiments. Gper-Cre mice were generated at Shanghai Model Organisms by knocking the 2A-Cre gene fragment into the Gper gene stop codon based on the CRISPR/Cas9 system and validated through GPER RNAscope in situ hybridization (Zheng et al., 2020). GPER−/− rats and mice were both constructed at BIORAY. GPER−/− rats (Luo et al., 2017) were generated through the CRISPR/Cas9 gene-editing approach with a 139-bp deletion of the Gper gene (gene ID:171104). GPER−/− mice were also generated by using the CRISPR/Cas9 system with a 17-bp deletion of the Gper gene (gene ID: 76854). WT rats and mice were provided by the Animal Facility of Shanghai Jiao Tong University School of Medicine. All animals were housed on a 12 h light/dark cycle with access to food and water ad libitum. All experiments were conducted in compliance with the governmental regulations on the use of experimental animals and were approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine.
Drug preparation
Serotonin hydrochloride (5-HT; catalog #H9523), chloroquine (catalog #C6628), histamine (catalog #H7125), compound 48/80 (catalog #C2313), diphenylcyclopropenone (DCP; catalog #177377) were purchased from Sigma-Aldrich. DCP was dissolved in acetone, and other reagents were dissolved in sterile saline. Clozapine N-oxide (CNO; catalog #C0832), the exogenous designer receptors exclusively activated by designer drugs (DREADD) ligand, was also from Sigma-Aldrich and dissolved in saline with gentle vortex for mixing. Imiquimod (IQM) cream was from Aldara, and Naltrexone HCl (catalog #S2103) was purchased from Selleck Chemicals. G15 (catalog #14673, Cayman Chemical,) was dissolved in DMSO as stock and diluted in saline before use. All viruses used in the experiment were provided by Shanghai Taitool Bioscience.
Acute chemical itch
Mice or rats were shaved on the back neck and handled daily for 5 d before the behavioral tests. During the tests, animals were allowed to acclimate to the environment for 20–30 min first and then were removed from the chamber and intradermally injected with different pruritic compounds, histamine (500 µg/20 µL), chloroquine (150 µg/20 µL), or compound 48/80 (50 µg/20 µL) for mice. Higher doses of histamine (600 µg) or chloroquine (200 µg) were given to the mice to observe whether chemogenetic activation of GPER+ neurons would attenuate acute chemical itch. For rats, the doses of the chemicals were the following: histamine (2.5 mg/50 µL), 5-HT (200 µg/50 µL), and chloroquine (2.5 mg/50 µL). Immediately after the injection, animals were placed individually in the observation boxes and videotaped for 30 min. The scratching bouts with the hindpaw directed to injection sites were counted by an investigator who was blinded to the genotypes and treatments.
Chronic itch models
For the DCP-induced contact dermatitis mouse model, animals were shaved on the back neck 3 d before sensitization and were handled daily. Mice were sensitized with 0.2 ml DCP (1% dissolved in acetone) by painting it on the shaved back neck. Seven d after the sensitization, the back neck was painted with 0.2 ml of 0.5% DCP on days 1, 4, 5, 6, 7, 10, 11, and 14 (Liu et al., 2016). The animals were placed individually in the observation box after painting each day and videotaped for 1 h. Spontaneous scratching behaviors were recorded on day 15 for 1 h. As with the mouse experiment, rats were sensitized with 0.5 ml DCP (4% dissolved in acetone). Seven d after the sensitization the back neck was painted with 0.5 ml of 2% DCP for 7 consecutive days. Scratching bouts were counted for 1 h each day after painting. Spontaneous scratching behaviors were recorded on day 8 for 1 h. For the imiquimod-induced psoriasis model, the back neck was also shaved and received topical application of 12.5 mg imiquimod daily for 7 consecutive days (mice for 6 d with 6 mg imiquimod). Spontaneous scratch bouts were recorded before painting the back neck with imiquimod cream on every testing day. The investigator who counted the itch behavior was blinded to the genotypes and treatments.
Acute mechanical itch (alloknesis)
To test acute mechanical itch, mice or rats were shaved on the back neck and allowed to acclimate to the environment for 20 min daily for 3 consecutive days before the experiment. On the testing day, the back neck was probed with light von Frey filaments (Aesthesio). Each stimulus was applied 1 s and repeated 5 times at 5 s intervals. Hindpaw scratching toward the poked site was considered a positive response. The experimenter was blinded to the genotypes.
Tail-flick test
Mice were habituated to the testing room and handled before the test. On the testing day, mice were gently restrained in experimenter's hand with a cotton glove. The protruding one-third of the tail was then immersed into a water bath (52°C), the latency of tail flick response was measured, with a cutoff time of 10 s to avoid tissue damage. The experimenter was blinded to the genotypes in this experiment.
Hematoxylin and eosin staining
Rats or mice were perfused with normal saline followed by 4% paraformaldehyde after an overdose of sodium pentobarbital. The skin of the back neck was removed and postfixed in 4% PFA. The tissue was embedded in paraffin and then consecutively sectioned into 15 µm slices. The tissue slices were then stained with commercial reagents for hematoxylin and eosin (HE) according to the instructions in the manual. Tissue histology was observed under a microscope (Leica DM2500, Leica Microsystems), photographed and analyzed by an investigator who was blinded to the genotypes and treatments. For the DCP-induced contact dermatitis models, the skin lesion severity was evaluated using a 4-point scoring system (Mann et al., 2012). Briefly, 0 denotes normal skin histology and 1–4 denotes increasing severity of tissue damage and inflammation, that is, at 1, the epidermis is slightly thickened with slight inflammatory infiltration; 2, thickening of epidermis is easily identified with moderate inflammatory cell infiltration but minimal epidermal damage; 3, there is moderate epidermal damage and more inflammatory cell infiltration; and 4, more than 50% of the epidermal layer is damaged with intense inflammatory cells infiltration. For the IMQ-induced psoriasis models, the skin pathology was evaluated according to the Psoriasis Area Severity Index scoring system (Fredriksson and Pettersson, 1978). Erythema, infiltration, and desquamation were scored separately on a scale from 0 to 4, with 0 indicating none; 1, slight; 2, moderate; 3, marked; and 4, very marked. The total score indicates the severity of skin pathology.
Immunofluorescence
Rats or mice were killed with an overdose of sodium pentobarbital and were then perfused with saline followed by 4% paraformaldehyde. Brainstems were removed and postfixed in 4% PFA at 4°C overnight, followed by cryoprotection in 30% sucrose. The tissue of interest was cut into 25 µm slices. The slices were blocked with 50 mm PBS containing 10% normal goat or donkey serum and 1% Triton X-100 at room temperature for 2 h, followed by incubation with primary antibodies at 4°C overnight and secondary antibodies at room temperature for 2 h. Primary antibodies used in these experiments were rabbit anti-GPER (1:500; catalog #LS-A4272, Lifespan), mouse anti-c-fos (1:500; catalog #ab208942, Abcam), rabbit anti-c-fos (1:1000; catalog #2250S, Cell Signaling Technology), mouse anti-GAD67 (1:500; catalog #MAB5406, Millipore), goat anti-5-HT (1:1000; catalog #GT-20 079, Neuromics), guinea pig anti-MOR (1:500; catalog #GP10106, Neuromics) and mouse anti-Leu enkephalin antibody (1:100; catalog #ab150346, Abcam). The secondary antibodies included donkey anti-goat 568 (1:1000; catalog #A11057, Invitrogen), donkey anti-rabbit 488 (1:1000; catalog #A21206, Invitrogen), goat anti-rabbit 488 (1:1000; catalog #A11034, Invitrogen), goat anti-mouse 568 (1:1000; catalog #A11031, Invitrogen), and goat anti-guinea pig 568 (1:1000; catalog #A11075, Invitrogen). The nuclei were stained with DAPI (1:1000; catalog #PA5-62248, Thermo Fisher Scientific). Images were visualized under a fluorescent microscope (Leica DM2500, Leica Microsystems). Specificity of the primary antibodies for c-fos, GAD67, and MOR immunofluorescence has been validated in numerous previous studies (Nassirpour et al., 2010; Wei et al., 2015; An et al., 2020). Among several commercial primary antibodies for GPER we have tested, LS-A4272 was chosen for GPER immunofluorescence as it seemed to produce the least nonspecific staining. Furthermore, we found that the distribution of GPER immunofluorescence in various tissues using LS-A4272 was consistent with GPER mRNA expression (Zheng et al., 2020).
Western blot
Total protein from freshly dissected RVM was isolated, and the protein concentration was determined using the BCA Protein Assay (Pierce). Twenty-five µg of total proteins was electrophoresed on a 10% SDS-PAGE gel and transferred onto a PVDF membrane and then blocked with 5% nonfat dried milk or 5% BSA. Subsequently, the membranes were incubated with the following different primary antibodies for 24 h at 4°C: rabbit anti-GPER (1:1000; catalog #ab39742, Abcam), rabbit anti-phosphorylated MOR (pMOR; 1:1000; catalog #3451, Cell Signaling Technology), rabbit anti-MOR (1:500; catalog #NBP1-31180, Novus Biologicals) and mouse anti-β-actin (1:3000; catalog #BS6007M, Bioworld Technology), followed by the following peroxidase-conjugated secondary antibodies: anti-rabbit (1:3000; catalog #170-6515, Bio-Rad,) or anti-mouse (1:3000; catalog #170-6516, Bio-Rad). Immunoreactive bands were visualized using chem-iluminescence reagent (Thermo). The peptide preabsorption test was conducted to identify the specific band for GPER. The immunoreactive bands for MOR and pMOR were determined by their predicted molecular weight and according to the manufacturer's data sheets. The density of specific bands was analyzed using National Institutes of Health ImageJ software and was normalized against the loading controls (β-actin).
TUNEL staining
Apoptotic GPER+ neurons were analyzed using a terminal deoxynucleotidyl transferase-mediated uridine 5′-triphosphate-biotin nick end labeling (TUNEL) assay kit (In Situ Cell Death Detection, Fluorescein). Briefly, after fixation in 4% PFA for 15 min, brain slices were rinsed with PBS three times and permeabilized with 0.1% Triton X-100 in PBS for 2 min. Then the slices were stained using the TUNEL staining kit and subsequently counterstained with DAPI for 10 min. Images were taken using a Leica fluorescent microscope (DM2500, Leica Microsystems).
Microinjection of virus into the RVM
We injected adeno-associated viruses (AAVs) to manipulate RVM neurons of 10-week-old mice, and the behavior tests were performed 4–5 weeks after viral injection. In brief, mice were anesthetized with 60 mg/kg pentobarbital sodium and secured in a stereotactic frame (RWD Life Science). The skull was exposed by a midline scalp incision, and a hole was drilled on the skull to allow passage of a glass pipette filled with the virus. Viral injections were performed using the following coordinates: −5.88 mm from bregma, 0 mm from midline, and 5.7 mm ventral to skull. The following viruses were used in this study: AAV-hSyn-hM4D(Gi)-mCherry (AAV2/9, 3.3 × 1012 v. × g./ml), AAV-hSyn-DIO-hM4D(Gi)-mCherry (AAV2/9, 1.82 × 1013 v. × g./ml), AAV-hSyn-DIO-hM3D(Gq)-eGFP (AAV2/9, 1.61 × 1013 v. × g./ml), or AAV-CAG-DIO-taCasp3-TEVp (AAV2/9, 3.7 × 1012 v. × g./ml). Injection volume was 400 nL. The pipette was left in place for ∼10 min after the injection, and the animals were allowed to recover under a heating lamp before returning to their home cage. The animals with incorrect injection sites were excluded for further analysis in all experiments.
PCR
For genotype identification of Gper-Cre mice, total DNA was extracted from the mouse tail, and then reverse transcription (RT)-PCR was performed, and the products were analyzed with agarose gel electrophoresis. The primers (5′ to 3′) used were as follows: Primer 1 (forward: CAGCTTCCTGGGAGAGACCTTCAG), Primer 2 (reverse: ACATGGTGCTCCCATAGCATGGCC), and Primer 3 (forward: AGAGTTCTCCATCAGGGATCTGAC). For verification of GPER−/− mice, total DNA was extracted from the mouse tail, and RT-PCR was performed. DNA sequencing was used to analyze the products. The primers (5′ to 3′) used were as follows: ACTAACAGGCTCCCAGGACGAT (forward) and CATCCAGGTGAGGAAGAAGACG (reverse). For verification of GPER−/−rats, total RNA was extracted from RVM with Trizol (Invitrogen) following the manufacturer's instructions. For reverse transcription, 500 ng of total RNA was used to synthesize cDNA by using the ThermoScript RT-PCR system kit (Invitrogen). Real-time RT-PCR followed by agarose gel electrophoresis was used to analyze the gene expression level. The relative level of Gper mRNA was calculated by the method of 2-ΔΔCt, and GAPDH was used as the loading control. The primer pairs (5′ to 3′) were the following: GAPDH: GTGATCGCTCTCTTCCTCTC (forward) and GTCTGGGATAGTCATCTTCTC (reverse), Primer 1 (GPER) CTGAACATCAGCAATATGTG (forward), and CTGATGTTCACCACCAAGA TG (reverse) cover the deletion fragment; Primer 2 (GPER)CATCCTCATCTTGGTGGTGAAC (forward) and CACCTCGATCAGGGAGTCGG (reverse) cover the deletion fragment; Primer 3 (GPER)CATCCTCATCTTGGTGGTGAAC (forward) and CACCTCGATCAGGGAGTCGG (reverse) cover the deletion fragment; and control primer CGCTCAAGGCAGTCATACCA (forward) and CCCCTGTCCGTTTTCCTCTA (reverse) cover the control fragment.
Statistics
Statistics were performed with GraphPad Prism version 8.0, and data are presented as mean ± SEM. All statistical analysis was two tailed. Paired or unpaired Student's t tests were used to compare two groups. For multiple comparisons, one-way ANOVA or two-way ANOVA was used, followed by Tukey's or Bonferroni's post hoc tests. A p value of <0.05 is considered an indication of statistical significance. Asterisks in figures denote p values as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Results
RVM is engaged in chronic itch conditions, and nonselective inhibition of RVM neurons increases mechanical alloknesis
The cellular organization of RVM in itch processing and the importance in pathologic itch is still poorly understood, despite evidence suggesting RVM serotonergic neurons may have a role facilitating itch. We asked whether the RVM would be engaged in chronic itch conditions and how nonselective inhibition of RVM neurons would have an impact on itch sensation. To address these questions, we first examined the expression of c-fos (a neuronal activity marker) in the RVM under chronic itch conditions. We found that the number of c-fos+ neurons in the RVM increased significantly in the DCP-induced chronic contact dermatitis (Sun et al., 2009) mouse and rat models (Fig. 1A–E). Next, we used a chemogenetic approach of DREADDs (Armbruster et al., 2007) to nonselectively inhibit resident RVM neurons. AAVs carrying the inhibitory DREADD receptor hM4Di fused with mCherry were injected into the RVM of wild-type (WT) mice (Fig. 1F,G) and mechanical itch was tested 30 min following administration of the hM4Di agonist CNO or saline 4 weeks after virus injection. Interestingly, we found that activation of hM4Di, thus nonselective inhibition of RVM neurons, led to significant increases in alloknesis scores induced by light mechanical stimulations (Fig. 1H). In contrast, tail-flick latency in response to noxious heat stimulation was significantly increased following activation of hM4Di (Fig. 1I). CNO was without significant effect on alloknesis in mice preinjected with the control virus (AAV-hSyn-mCherry; Fig. 1J). These results indicate that RVM is engaged in chronic itch conditions, and nonselective inhibition of RVM neurons has a net facilitatory effect on itch sensation, implying that there may indeed exist antipruritic neurons in RVM in addition to the pro-pruritic serotonergic neurons.
Selective ablation of RVM GPER+ neurons aggravates acute and chronic itch
In pilot experiments GPER was found to be enriched in rat RVM (Fig. 2A,B). Double immunofluorescent staining indicated that GPER+ neurons were nonserotonergic but largely GABAergic (Fig. 2C–E). In six sections from three rats, 147 GPER+ neurons and 226 5-HT+ neurons were counted, and none of these neurons showed colabeling. However, 74.8% of GPER+ neurons were also strongly immunoreactive to GAD67, a selective marker for GABAergic neurons, although GAD67+ neurons were much more numerous than GPER+ neurons in this region. To test whether GPER+ neurons in the RVM were involved in itch modulation, we conducted c-fos immunofluorescence to detect the activation of these neurons in itch conditions. We found that GPER+ neurons were significantly activated in DCP-induced chronic contact dermatitis in both rat and mouse models (Fig. 2F,G). It was estimated that 55.23 and 39.51% of GPER+ neurons were activated (c-fos+) in the rat and mouse chronic contact dermatitis models, respectively. Furthermore, 54.77 and 71.71% of c-fos+ neurons were GPER+ in the rat and mouse models, respectively, suggesting engagement of GPER+ neurons in chronic itch conditions.
Then we asked whether ablation of RVM GPER+ neurons would be sufficient to alter itch-related behavior. To address this question, Cre-dependent AAV-CAG-DIO-taCasp3-TEVp (Yang et al., 2013) was injected into the RVM of Gper-Cre mice (with WT mice as control) to selectively ablate the GPER+ neurons (Fig. 3A).
Western blot analysis conducted on day 35 following the viral infection showed a significant reduction of GPER protein level in the RVM of Gper-Cre mice injected with AAV-CAG-DIO-taCasp3-TEVp (Fig. 3B,C). Moreover, TUNEL staining further confirmed increased apoptosis of RVM neurons in the infected Gper-cre mice (Fig. 3D,E). We found that the number of hindpaw scratching bouts in response to light mechanical stimulations (0.08 × g and 0.3 × g) was increased significantly in Gper-Cre mice injected with AAV-CAG-DIO-taCasp3-TEVp compared with the WT mice injected with the same virus (Fig. 3F). Acute chemical itch behaviors in response to intradermal CQ and histamine were also increased in the Gper-Cre mice injected with the virus than in the WT mice (Fig. 3G,H). In a separate cohort of WT and Gper-Cre mice injected with the virus, we constructed a chronic contact dermatitis model by using DCP. Mice with selective ablation of GPER+ neurons showed more robust scratch bouts on every testing day compared with the WT mice (Fig. 3I–K). These results suggest that RVM GPER+ neurons likely play an antipruritic role, in contrast to the RVM serotonergic neurons, which have been shown to facilitate itch (Zhao et al., 2014).
Chemogenetic inhibition or activation of RVM GPER+ neurons differentially modulates itch-related behaviors
Considering that ablation of GPER+ neurons might cause an unpredictable disturbance of the neural circuitry, we next studied the effect of transient chemogenetic inhibition or activation of the RVM GPER+ neurons on chronic or acute itch.
Gper-Cre mice were injected with AAV-hSyn-DIO-hM4D(Gi)-mCherry into the RVM (Fig. 4A,B). Behavior tests were conducted 4 weeks after the virus injection. As shown in Figure 4C, 30 min after administration of the hM4D(Gi) agonist CNO to inhibit GPER+ neurons, the mice responded to light mechanical probing of the back neck by hindpaw scratching significantly more vigorously than mice treated with saline. In the same cohorts of mice, acute chemical itch was tested by intradermal injections of CQ or histamine (with 2 d of rest in between) 30 min after administration of CNO or saline. We found that the scratch bouts evoked by CQ and histamine were both significantly increased following chemogenetic inhibition of RVM GPER+ neurons (Fig. 4D,E). In the chronic contact dermatitis model, mice treated with DCP showed increased scratching behavior, and inhibition of RVM GPER+ neurons on day 5, 7, and 10 seemed to cause further increases in the number of scratching bouts (Fig. 4F), but the difference did not reach statistical significance.
We next observed the effects of chemogenetic activation of GPER+ neurons on itch-related behaviors. We selectively expressed the excitatory DREADD receptor hM3Dq in the RVM GPER+ neurons by microinjecting AAV-hSyn-DIO-hM3D(Gq)-eGFP into the RVM of Gper-Cre mice (Fig. 4G,H). Behavior tests were conducted 4 weeks after the viral infection, 30 min following intraperitoneal administration of CNO or saline. Compared with the saline-treated group, CNO-treated mice tended to show fewer scratching responses to light mechanical probing of the back neck, but the difference did not reach statistical significance, presumably because of the very low rate of scratching responses to light touch in these animals (Fig. 4I). However, CNO-treated mice showed a significantly decreased number of scratches induced by intradermal injection of CQ or histamine (Fig. 4J,K). In another cohort of mice injected with AAV-hSyn-DIO-hM3D(Gq)-eGFP, contact dermatitis was induced with repeated application of DCP for 14 d. On day 15, the animals were not painted with DCP but were injected intraperitoneally with CNO (to activate GPER+ neurons) or saline (as control) respectively; 30 min thereafter, the number of spontaneous scratches were counted for 1 h. The CNO-treated mice had significantly fewer hindpaw scratching bouts than the saline-treated mice (Fig. 4L).
GPER deficiency results in hypersensitivity to itch in mice and rats
We next asked the importance of GPER signaling in the regulation of itch. Western blot analysis showed that GPER protein expression in the RVM was significantly elevated in the DCP-induced contact dermatitis model in WT rats (Fig. 5A). These pilot data suggest that GPER signaling may be important in itch regulation. To further investigate the role of GPER signaling in acute and chronic itch, we used the GPER knock-out (GPER−/−) rats (Luo et al., 2017; Zheng et al., 2020) and mice. It is worth mentioning here that during daily handling or the acclimatization period before behavior tests, spontaneous scratches were as similarly rare in GPER−/− rats and mice as in their WT counterparts (Fig. 5B).
As shown in Figure 5C, GPER-deficient rats showed remarkable hypersensitivity to light mechanical probing of the back neck by hindpaw scratching compared with the WT rats. The number of scratches evoked by CQ, histamine, and 5-HT were also significantly increased in GPER−/− rats than in WT rats (Fig. 5D–F). In the DCP-induced chronic contact dermatitis model, GPER−/− rats showed significantly more robust scratching within 1 h after application of DCP than their WT counterparts on every testing day (Fig. 5G). Scratching bouts examined on day 8 (without application of DCP) were also markedly increased in the GPER−/− rats compared with the WT rats (Fig. 5H). The increased scratching behavior in the GPER−/− rats was accompanied by more severe skin lesions than the WT rats, likely because of more intense scratching (Fig. 5I–K). Similar results were obtained in the imiquimod-induced psoriasis model (Fig. 6). Thus, scratching bouts before or immediately after painting with imiquimod on all the testing days were all increased (Fig. 6B,C), accompanied by increased epidermis thickness in the GPER−/− rats compared with the WT rats (Fig. 6D–F). We have shown above that GPER+ neurons, likely having an antipruritic role, were significantly activated in a rat model of chronic itch (Fig. 2F). Interestingly, in the DCP-induced contact dermatitis model, GPER−/− rats showed significantly fewer c-fos+ neurons than WT rats in the RVM (Fig. 7), indicating that GPER may be indispensable for the mobilization of descending inhibition of itch.
Similar to the observations in GPER−/− rats, we found that GPER−/− mice exhibited hypersensitivity to chemical and mechanical itch (Fig. 8A,C) and increased scratching in the imiquimod-induced psoriasis model (Fig. 8D–G). In WT mice, blockade of GPER by systemic administration of G15 (0.5 mg/kg, i.p.), a GPER antagonist (Dennis et al., 2009), resulted in significant increases in scratching bouts following intradermal injection of the pruritogen compound 48/80 (Fig. 8B). Importantly, although the data presented as far were obtained from female animals, parallel studies were also conducted in male animals. We found that male GPER−/− mice and rats also exhibited mechanical alloknesis, hypersensitivity to chemical pruritogens, and greatly increased scratching bouts in the chronic itch models (Figs. 8H–J, 9A–E). Thus, these effects are species and sex independent.
GPER modulates itch through regulating µ opioid signaling
We then set to test the hypothesis that GPER may signal through desensitizing MOR (Ding et al., 2019) in the RVM to regulate itch sensation. By immunofluorescence, we found that virtually all GPER+ neurons within the rat RVM were strongly immunoreactive for MOR, although MOR+ neurons were much more numerous than GPER+ neurons (∼20% MOR+ neurons were GPER+; Fig. 10A). Furthermore, double immunohistochemistry (IHCs) showed there were enkephalinergic terminals in proximity to GPER+ neurons (Fig. 10B). Western blot analysis of the RVM protein lysates showed that MOR expression was significantly decreased, whereas pMOR expression was markedly increased in WT rats with chronic contact dermatitis compared with the WT control rats. Strikingly, in the chronic contact dermatitis model, GPER−/− rats did not show significant MOR phosphorylation in RVM (Fig. 10C–F). These results indicate that chronic itch may trigger decreased µ opioid signaling in the RVM, and GPER is required in this process. In other words, the itch phenotype of GPER−/− mice and rats may be because of enhanced MOR signaling. Consistent with this observation, we found that the mechanical alloknesis, the hypersensitivity to histamine and the increased chronic itch in DCP-induced contact dermatitis seen in GPER−/− rats or mice were all reversed by the µ opioid antagonist naltrexone (Fig. 11A–D). However, scratching responses to light mechanical stimulations in the WT mice were not affected by naltrexone treatment (Fig. 11E,F).
Discussion
Itch processing in the brain is immensely complex. Recent evidence suggests that the PAG-RVM system, originally known for its bidirectional roles in descending modulation of pain, may also be important in the regulation of itch (Zhao et al., 2014; Follansbee et al., 2018; Gao et al., 2019). The current study has provided evidence that GPER-expressing neurons (largely GABAergic) in the RVM are antipruritic neurons. These neurons are mobilized in chronic itch conditions, likely through GPER-dependent desensitization of µ opioid signaling. The findings provide a new concept in itch regulation that there is a counter mechanism to balance the excitatory action by serotonergic neurons in the PAG-RVM system and that GPER is essential for mobilizing descending inhibition of itch.
RVM GPER+ neurons play essential roles in descending inhibition of itch
We found that c-fos expression was increased in the RVM in the DCP-induced chronic contact dermatitis model in both rats and mice, suggesting that RVM is engaged in chronic itch conditions. Whether itch signal per se or scratch-induced pain/tissue damage resulted in activation of RVM neurons is not clear. But the focus here should be that the activated (c-fos+) neurons are deemed to play certain roles in itch regulation, either excitatory or inhibitory. RVM serotonergic neurons facilitate transmission of itch signals in the spinal cord, and loss of this facilitatory influence reduces itch (Liu et al., 2014; Zhao et al., 2014). However, we found that nonserotonergic neurons rather than serotonergic neurons were activated in the chronic itch model. We argue that this may imply mobilization of nonserotonergic antipruritic neurons in chronic itch conditions. Global suppression of RVM neurons by the DREADD method was found to result in hypersensitivity to mechanical itch. Hence, it seems possible that the antipruritic neurons may be constitutively active and that loss of this antipruritic tone may facilitate itch. Understanding the nature of the antipruritic neurons and the molecular mechanisms underlying the tonic activity and mobilization of these neurons may hold the key to effective management of itch.
Until now, the cellular organization of the RVM in relation to pain or itch control remains poorly understood because of the lack of selective molecular markers for different types of neurons within this region, except for the serotonergic neurons (Francois et al., 2017; Chen and Heinricher, 2019). The current study tends to support GPER as a molecular marker for a population of antipruritic neurons within the RVM. This argument is based on three complementary lines of evidence. First, GPER was found to be exclusively confined to nonserotonergic neurons. Second, selective ablation of GPER+ neurons by Cre-driven overexpression of Caspase3 resulted in mechanical alloknesis, hypersensitivity to chemical pruritogens, and increased itch-related behaviors in the DCP-induced contact dermatitis model. Third, selective chemogenetic manipulation of the activity of these neurons also led to behavioral changes consistent with GPER+ neurons' having an antipruritic role. In the mechanical alloknesis test, light mechanical probing of the back neck mimics normal physiological situations, such as a light breeze over the skin. That this behavior was also altered by chemogenetic manipulations of GPER+ neurons indicate that these neurons may play a role in itch regulation under normal physiological as well as in pathologic conditions.
Two functional types of neurons, namely ON and OFF neurons, are presumed to facilitate and inhibit pain transmission in the spinal cord, respectively (Fields et al., 1983, 1991; Mason et al., 1992). But these neurons may not be specific for pain regulation (Mason, 2005). It has been shown that intradermal pruritogens may cause excitation of a large proportion of electrophysiologically identified ON neurons and inhibition of a smaller proportion of OFF neurons, suggesting that at least subpopulations of ON and OFF neurons may regulate itch as well as pain (Follansbee et al., 2018). The observation also implies that the peripheral itch signal may mobilize a subset of ON neurons, presumably to inhibit the itch sensation. The GPER+ neurons likely correspond to this subset of ON neurons because they were mobilized, as evidenced by c-fos expression, in the chronic contact dermatitis model in both rats and mice. Although the current study focused on itch regulation, we do not persist with the idea that GPER+ neurons specifically inhibit itch. Rather, they might play dual roles in sensory processing, inhibition of itch, and facilitation of pain.
We found that GPER+ neurons likely are GABAergic neurons as they were mostly immunoreactive to GAD67. RVM GABAergic neurons are heterogeneous in function and in neurochemistry (Pedersen et al., 2011). Interestingly, previous studies suggest that the spinal cord dorsal horn receives substantial GABAergic input from the RVM (Reichling and Basbaum, 1990; Pedersen et al., 2011). Indeed, more than half of both ON and OFF cells may be GABAergic (Winkler et al., 2006). Francois et al. (2017) demonstrated that activation of RVM GABAergic neurons facilitated mechanical pain by inhibiting dorsal horn enkephalinergic and GABAergic interneurons, whereas Zhang et al. (2015) showed that dual GABA/enkephalinergic RVM neurons could inhibit behavioral sensitivity to heat and mechanical stimuli. Moreover, in addition to the excitatory serotonergic projections, RVM GABAergic fibers form functional inhibitory synapses with spinal GRPR+ neurons, which are critical for the coding of itch sensation in the spinal cord (Sun and Chen, 2007; Liu et al., 2019). These bulbospinal GABAergic neurons were presumed to mediate inhibition of itch (Samineni et al., 2019). Conceivably, GPER+ neurons may correspond to this neuronal population.
GPER is required for the mobilization of descending inhibition of itch through desensitizing µ opioid signaling
GPER has been shown to mediate rapid estrogenic effects in a variety of tissues including in the nervous system (Brailoiu et al., 2007; Dun et al., 2009; Takanami et al., 2010; Paletta et al., 2018). We found that GPER expression in RVM was significantly increased in chronic itch conditions. Moreover, GPER-deficient rats and mice both exhibited a hypersensitive itch phenotype in acute (mechanical and chemical) and chronic itch models. In the DCP-induced contact dermatitis model, GPER−/− rats showed significantly fewer c-fos+ neurons than WT rats in the RVM. These results indicate that GPER signaling is important in regulation of GPER+ neuronal activity and is critical for mobilization of descending inhibition of itch.
Activation of GPER likely promotes activation of GPER+ neurons and mobilization of descending inhibition of itch through disinhibition from opioid inputs. Opioid signaling is predominant within the PAG-RVM pathway and activation of the inhibitory MOR mediates potent analgesia but induces itch (Ko et al., 2004; Miyamoto and Patapoutian, 2011). We detected dense enkephalinergic terminals in proximity to GPER+ neurons, suggesting that GPER+ neurons, which express MOR, receive direct inhibitory opioidergic inputs. MOR inhibits neuronal activity by interacting with G-protein-regulated inwardly rectifying potassium (GIRK) channels (Montandon et al., 2016). Protein kinase-dependent MOR phosphorylation results in desensitization of the receptor (Arttamangkul et al., 2018). Estradiol may rapidly uncouple MOR from activating potassium currents in hypothalamic neurons (Lagrange et al., 1997), and we have found that activation of GPER promotes MOR phosphorylation in SH-SY5Y cells (Ding et al., 2019). Meanwhile, in the current study, we found that MOR phosphorylation was significantly increased in WT but not in GPER−/− rats with chronic contact dermatitis. Furthermore, the hypersensitive itch phenotype of GPER−/− rats and mice was reversed by the µ antagonist naltrexone. These results together suggest that GPER may signal through desensitizing MOR thereby to promote the excitability and mobilization of the antipruritic GPER+ neurons.
Interestingly, we found that male and female GPER-deficient rats and mice exhibited a similar hypersensitive itch phenotype. Therefore, GPER signaling in descending control of itch is ubiquitous across species and sex and may be of fundamental biological significance. We reason that the antipruritic GPER+ neurons may play critical roles in gating ascending itch signal transmission, and they are under tonic inhibitory opioidergic influences mediated by MOR. In normal conditions GPER-mediated MOR phosphorylation may cause some degree of disinhibition of GPER+ neurons from the opioidergic inputs thereby to maintain a descending antipruritic tone to prevent animals from being overresponsive to harmless environmental cues. GPER-mediated disinhibition is upregulated in chronic itch conditions, allowing for the mobilization of this critical descending inhibitory pathway.
In summary, this investigation has provided evidence showing that the GPER+ neurons in the RVM play a crucial inhibitory role in descending regulation of itch. Activation of GPER promotes phosphorylation of MOR and disinhibition of the antipruritic GPER+ neurons from opioidergic inputs. This mechanism seems essential in the regulation of itch in normal and pathologic conditions.
Footnotes
This work was supported by the National Natural Science Foundation of China (Grants 81570493 and 81873728), the Science and Technology Commission of Shanghai Municipality (Grant 18JC1420302), and Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Grant JZPI201705). C.W. was supported by the Biotechnology and Biological Sciences Research Council (BB/P004695/1) and National Institute of Aging (1R01AG049321-01A1).
The authors declare no competing interests.
- Correspondence should be addressed to Weifang Rong at weifangrong{at}shsmu.edu.cn or Xueyin Shi at shixueyin1128{at}163.com